BlinkLab (ASX:BB1) said the North Shore Pediatric Therapy joined its US clinical study, and it is expected to enroll patients in the coming weeks, according to a Monday Australian bourse filing.
As part of the US registrational study, North Shore's use of the ADOS-2 diagnostic tool will serve as a critical benchmark for standard-of-care comparisons, the filing said.
North Shore, a provider of pediatric services, specializing in the evaluation and treatment of autism, is the second US-based site to join the 100-patient initial phase of the registrational study.
The clinic also provides access to a diverse population of children throughout the Chicago area, ensuring the study reflects a broad range of backgrounds and developmental profiles.
The firm's shares rose 8% on market close on Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。